Progress in research and development of temozolomide brain-targeted preparations: a review

References

• Latifyan S, de Micheli R, Hottinger AF. Physical approaches to treat glioblastoma. Curr Opin Oncol. 2020;32(6):640–649.
   PubMed Web of Science ®Google Scholar
• Touat M, Li YY, Boynton AN, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517–523.
   PubMed Web of Science ®Google Scholar
• Huang B, Abraham WD, Zheng Y, et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 2015;7(291):291r–294r.
   Web of Science ®Google Scholar
• Afergan E, Epstein H, Dahan R, et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release. 2008;132(2):84–90.
   PubMed Web of Science ®Google Scholar
• Wang C, Li K, Li T, et al. Monocyte-mediated chemotherapy drug delivery in glioblastoma. Nanomedicine (Lond). 2018;13(2):157–178.
   PubMed Web of Science ®Google Scholar
• Drapeau AI, Poirier M, Madugundu G, et al. Intra-arterial temozolomide, osmotic blood-brain barrier disruption and radiotherapy in a rat F98-Glioma model. Clin Cancer Drugs. 2018;4(2):135–144.
   Google Scholar
• Braatz D, Cherri M, Tully M, et al. Chemical approaches to synthetic drug delivery systems for systemic applications. Angew Chem Int Ed. 2022. DOI:10.1002/anie.202203942
   PubMed Web of Science ®Google Scholar
• Pandit R, Chen L, Götz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. 2020;165–166:1–14.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Peng Z, Seven ES, et al. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290–303. doi:10.1016/j.jconrel.2017.12.015
   PubMed Web of Science ®Google Scholar
• Darkes MJM, Plosker GL, Jarvis B. Temozolomide. Am J Cancer. 2002;1(1):55–80.
   Google Scholar
• Jones SF, Greco FA, Gian VG, et al. A phase I trial of protracted oral fixed-dose temozolomide. Cancer. 2005;104(9):1985–1991.
   PubMed Web of Science ®Google Scholar
• Chen C, Yin S, Zhang S, et al. Treatment of aggressive prolactinoma with temozolomide. Medicine (Baltimore). 2017;96(47):e8733.
   PubMed Web of Science ®Google Scholar
• Hotchkiss KM, Sampson JH. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J Neurooncol. 2021;151(1):55–62.
   PubMed Web of Science ®Google Scholar
• Tomar MS, Kumar A, Srivastava C, et al. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188616.
   PubMed Web of Science ®Google Scholar
• Wang H, Lin Y, Lin W, et al. Tumor volume changes during and after temozolomide treatment for newly diagnosed higher-grade glioma (III and IV). World Neurosurg. 2018;114:e766–e774.
   PubMed Web of Science ®Google Scholar
• Seiter K, Liu D, Loughran T, et al. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol. 2002;20(15):3249–3253.
   PubMed Web of Science ®Google Scholar
• Das L, Gupta N, Dutta P, et al. Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas. Front Endocrinol (Lausanne). 2021;12:774686.
   PubMed Web of Science ®Google Scholar
• Gogas H, Polyzos A, Stavrinidis I, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the hellenic cooperative oncology group. Ann Oncol. 2006;17(12):1835–1841.
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19):6767–6771.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhong Y, Chen Y, et al. Ligand-modified erythrocyte membrane-cloaked metal–organic framework nanoparticles for targeted antitumor therapy. Mol Pharm. 2020;17(9):3328–3341.
   PubMed Web of Science ®Google Scholar
• Happold C, Stojcheva N, Silginer M, et al. Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. J Neurochem. 2018;144(6):780–790.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
   PubMed Web of Science ®Google Scholar
• Felsberg J, Thon N, Eigenbrod S, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129(3):659–670.
   PubMed Web of Science ®Google Scholar
• Mcdonald KL, Tabone T, Nowak AK, et al. Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation. Oncol Lett. 2015;9(5):2063–2067.
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793–797.
   PubMed Web of Science ®Google Scholar
• Gupta D, Heinen CD. The mismatch repair-dependent DNA damage response: mechanisms and implications. DNA Repair (Amst). 2019;78:60–69.
   PubMed Web of Science ®Google Scholar
• Ortiz R, Perazzoli G, Cabeza L, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19(4):513–537.
   PubMed Web of Science ®Google Scholar
• Lavrik OI. PARPs’ impact on base excision DNA repair. DNA Repair (Amst). 2020;93:102911.
   PubMed Web of Science ®Google Scholar
• Yuan AL, Meode M, Tan M, et al. PARP inhibition suppresses the emergence of temozolomide resistance in a model system. J Neurooncol. 2020;148(3):463–472.
   PubMed Web of Science ®Google Scholar
• He L, Zhou H, Zeng Z, et al. Wnt/β–catenin signaling cascade: a promising target for glioma therapy. J Cell Physiol. 2019;234(3):2217–2228.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu L, Lao Y, et al. Natural products targeting EGFR signaling pathways as potential anticancer drugs. Curr Protein Pept Sci. 2018;19(4):380–388.
   PubMed Web of Science ®Google Scholar
• Duwa R, Banstola A, Emami F, et al. Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells. J Drug Delivery Sci Technol. 2020;60:101928.
   Web of Science ®Google Scholar
• Zamame Ramirez JA, Romagnoli GG, Kaneno R. Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy. Life Sci. 2021;265:118745.
   PubMed Web of Science ®Google Scholar
• Würstle S, Schneider F, Ringel F, et al. Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner. Oncol Lett. 2017;14(1):322–328.
   PubMed Web of Science ®Google Scholar
• Liebelt BD, Shingu T, Zhou X, et al. Glioma stem cells: signaling, microenvironment, and therapy. Stem Cells Int. 2016;2016:7849890–7849810.
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–284.
   PubMed Web of Science ®Google Scholar
• Chien C, Hsueh W, Chuang J, et al. Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. J Biomed Sci. 2021;28(1):18.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Gabizon A. Targeting of liposomes to tumor cells in vivoa. Ann N Y Acad Sci. 1987;507(1):64–74.
   PubMedGoogle Scholar
• Khan AA, Allemailem KS, Almatroodi SA, et al. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech. 2020;10(4):163.
   PubMedGoogle Scholar
• Gulati M, Bajad S, Singh S, et al. Development of liposomal amphotericin B formulation. J Microencapsul. 1998;15(2):137–151.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. Vincristine sulfate liposome injection (VSLI, marqibo®) facilitates increased delivery of vincristine sulfate to target cancer tissues. Blood. 2012;120(21):2457–2457.
   Web of Science ®Google Scholar
• Gao J, Wang Z, Liu H, et al. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug Discov Ther. 2015;9(3):205–212.
   PubMed Web of Science ®Google Scholar
• Ewert KK, Scodeller P, Simón-Gracia L, et al. Cationic liposomes as vectors for nucleic acid and hydrophobic drug therapeutics. Pharmaceutics. 2021;13(9):1365.
   PubMed Web of Science ®Google Scholar
• Tapeinos C, Marino A, Battaglini M, et al. Stimuli-responsive lipid-based magnetic nanovectors increase apoptosis in glioblastoma cells through synergic intracellular hyperthermia and chemotherapy. Nanoscale. 2018;11(1):72–88.
   PubMed Web of Science ®Google Scholar
• Ma J, Deng H, Zhao F, et al. Liposomes-camouflaged redox-responsive nanogels to resolve the dilemma between extracellular stability and intracellular drug release. Macromol. Biosci. 2018;18(7):1800049.
   Web of Science ®Google Scholar
• Sivadasan D, Sultan MH, Madkhali OA, et al. Stealth liposomes (PEGylated) containing an anticancer drug camptothecin: in vitro characterization and in vivo pharmacokinetic and tissue distribution study. Molecules. 2022;27(3):1086.
   PubMed Web of Science ®Google Scholar
• Wang L, Tang S, Yu Y, et al. Intranasal delivery of temozolomide-conjugated gold nanoparticles functionalized with anti-EphA3 for glioblastoma targeting. Mol Pharm. 2021;18(3):915–927.
   PubMedGoogle Scholar
• Chu L, Wang A, Ni L, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 2018;25(1):1634–1641.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Gupta L, Sahu H, et al. Chitosan engineered PAMAM dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide. Pharm Res. 2018;35(1):9.
   PubMed Web of Science ®Google Scholar
• Huang R, Ke W, Han L, et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metab. 2009;29(12):1914–1923.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhou H, Hou X, et al. Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment. Cancer Lett. 2018;423:16–26.
   PubMed Web of Science ®Google Scholar
• Meena J, Gupta A, Ahuja R, et al. Inorganic nanoparticles for natural product delivery: a review. Environ Chem Lett. 2020;18(6):2107–2118.
   Web of Science ®Google Scholar
• Hwang SR, Chakraborty K, An JM, et al. Pharmaceutical aspects of nanocarriers for smart anticancer therapy. Pharmaceutics. 2021;13(11):1875.
   PubMed Web of Science ®Google Scholar
• Pineau P, Volinia S, Mcjunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107(1):264–269.
   PubMed Web of Science ®Google Scholar
• Berbel Manaia E, Paiva Abuçafy M, Chiari-Andréo BG, et al. Physicochemical characterization of drug nanocarriers. Int J Nanomed. 2017;12:4991–5011. volume
   PubMed Web of Science ®Google Scholar
• Wang L, Liu J, Sui L, et al. Folate-modified graphene oxide as the drug delivery system to load temozolomide. Curr Pharm Biotechnol. 2020;21(11):1088–1098.
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.
   PubMed Web of Science ®Google Scholar
• Touitou E, Illum L. Nasal drug delivery. Drug Deliv Transl Res. 2013;3(1):1–3.
   PubMed Web of Science ®Google Scholar
• Akashi K, Miyata H, Itoh H, et al. Formation of giant liposomes promoted by divalent cations: critical role of electrostatic repulsion. Biophys J. 1998;74(6):2973–2982.
   PubMed Web of Science ®Google Scholar
• Simonis B, Vignone D, Gonzalez Paz O, et al. Transport of cationic liposomes in a human blood brain barrier model: role of the stereochemistry of the gemini amphiphile on liposome biological features. J Colloid Interface Sci. 2022;627:283–298.
   PubMed Web of Science ®Google Scholar
• Perini G, Giulimondi F, Palmieri V, et al. Inhibiting the growth of 3D brain cancer models with bio-coronated liposomal temozolomide. Pharmaceutics. 2021;13(3):378.
   PubMed Web of Science ®Google Scholar
• Hathout RM, Gad HA, Metwally AA. Gelatinized-core liposomes: toward a more robust carrier for hydrophilic molecules. J Biomed Mater Res A. 2017;105(11):3086–3092.
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
   PubMed Web of Science ®Google Scholar
• Vanza J, Jani P, Pandya N, et al. Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design. Drug Dev Ind Pharm. 2018;44(6):923–933.
   PubMed Web of Science ®Google Scholar
• Yang T, Cui F, Choi M, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338(1–2):317–326.
   PubMed Web of Science ®Google Scholar
• Rezaei FS, Sharifianjazi F, Esmaeilkhanian A, et al. Chitosan films and scaffolds for regenerative medicine applications: a review. Carbohydr Polym. 2021;273:118631.
   PubMed Web of Science ®Google Scholar
• Rajitha P, Gopinath D, Biswas R, et al. Chitosan nanoparticles in drug therapy of infectious and inflammatory diseases. Expert Opin Drug Deliv. 2016;13(8):1177–1194.
   PubMed Web of Science ®Google Scholar
• Gondil VS, Dube T, Panda JJ, et al. Comprehensive evaluation of chitosan nanoparticle based phage lysin delivery system; a novel approach to counter S. pneumoniae infections. Int J Pharm. 2020;573:118850.
   PubMed Web of Science ®Google Scholar
• Abdou EM, Kandil SM, Miniawy HMFE. Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion. Int J Pharm. 2017;529(1–2):667–677.
   PubMed Web of Science ®Google Scholar
• Thongborisute J, Takeuchi H, Yamamoto H, et al. Visualization of the penetrative and mucoadhesive properties of chitosan and chitosan-coated liposomes through the rat intestine. J Liposome Res. 2006;16(2):127–141.
   PubMed Web of Science ®Google Scholar
• Qian S, Zhang Q, Wang Y, et al. Bioavailability enhancement of glucosamine hydrochloride by chitosan. Int J Pharm. 2013;455(1–2):365–373.
   PubMed Web of Science ®Google Scholar
• Yu S, Xu X, Feng J, et al. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int J Pharm. 2019;560:282–293.
   PubMed Web of Science ®Google Scholar
• Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci. 2021;22(17):9652.
   PubMed Web of Science ®Google Scholar
• Ke C, Deng F, Chuang C, et al. Antimicrobial actions and applications of chitosan. Polymers. 2021;13(6):904.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao T, Liu Y, et al. Ursolic acid liposomes with chitosan modification: promising antitumor drug delivery and efficacy. Mater Sci Eng C Mater Biol Appl. 2017;71:1231–1240.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng F, Wang X, et al. Chitosan decoration improves the rapid and long-term antibacterial activities of cinnamaldehyde-loaded liposomes. Int J Biol Macromol. 2021;168:59–66.
   PubMed Web of Science ®Google Scholar
• Fang Y, Xue J, Gao S, et al. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv. 2017;24(Suppl 1):22–32.
   PubMedGoogle Scholar
• Jiao J, Jiao X, Wang C, et al. The contribution of PEG molecular weights in PEGylated emulsions to the various phases in the accelerated blood clearance (ABC) phenomenon in rats. AAPS PharmSciTech. 2020;21(8):300.
   PubMed Web of Science ®Google Scholar
• Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710–724.
   PubMed Web of Science ®Google Scholar
• Amarandi R, Ibanescu A, Carasevici E, et al. Liposomal-based formulations: a path from basic research to temozolomide delivery inside glioblastoma tissue. Pharmaceutics. 2022;14(2):308.
   PubMed Web of Science ®Google Scholar
• Li T, Li K, Zhang Q, et al. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma. Biomaterials. 2018;181:35–52.
   PubMed Web of Science ®Google Scholar
• Cao J, Su T, Zhang L, et al. Polymeric micelles with citraconic amide as pH-sensitive bond in backbone for anticancer drug delivery. Int J Pharm. 2014;471(1–2):28–36.
   PubMedGoogle Scholar
• Prabaharan M, Grailer JJ, Pilla S, et al. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials. 2009;30(29):5757–5766.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang H, Liu J, et al. Comb-like amphiphilic copolymers bearing acetal-functionalized backbones with the ability of acid-triggered hydrophobic-to-hydrophilic transition as effective nanocarriers for intracellular release of curcumin. Biomacromolecules. 2013;14(11):3973–3984.
   PubMed Web of Science ®Google Scholar
• Weis P, Wu S. Light-switchable azobenzene-containing macromolecules: from UV to near infrared. Macromol. Rapid Commun. 2018;39(1):1700220.
   Web of Science ®Google Scholar
• Ai X, Mu J, Xing B. Recent advances of light-mediated theranostics. Theranostics. 2016;6(13):2439–2457.
   PubMed Web of Science ®Google Scholar
• Ren K, Qiu Y, Yu Q, et al. Macrophage-mediated multi-mode drug release system for photothermal combined with anti-inflammatory therapy against postoperative recurrence of triple negative breast cancer. Int J Pharm. 2021;607:120975.
   PubMedGoogle Scholar
• Li X, Yang C, Tao Y, et al. Near-infrared light-triggered thermosensitive liposomes modified with membrane peptides for the local chemo/photothermal therapy of melanoma. Onco Targets Ther. 2021;14:1317–1329. volume
   PubMed Web of Science ®Google Scholar
• Nikolskaya ED, Zhunina OA, Vasilenko EA, et al. Preparation of temozolomide-loaded polymer particles and study of their antitumor activity in models of glioma and melanoma. Russ J Bioorg Chem. 2017;43(5):552–560.
   Web of Science ®Google Scholar
• Jin Y, Song L, Su Y, et al. Oxime linkage: a robust tool for the design of pH-sensitive polymeric drug carriers. Biomacromolecules. 2011;12(10):3460–3468.
   PubMed Web of Science ®Google Scholar
• Lee I, Park M, Kim Y, et al. Ketal containing amphiphilic block copolymer micelles as pH-sensitive drug carriers. Int J Pharm. 2013;448(1):259–266.
   PubMedGoogle Scholar
• Du K, Xia Q, Sun J, et al. Visible light and glutathione dually responsive delivery of a polymer-conjugated temozolomide intermediate for glioblastoma chemotherapy. ACS Appl Mater Interfaces. 2021;13(47):55851–55861.
   PubMed Web of Science ®Google Scholar
• Di Martino A, Kucharczyk P, Capakova Z, et al. Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles. J Nanopart Res. 2017;19(2):71.
   PubMed Web of Science ®Google Scholar
• Liu Q, Kim Y, Im G, et al. Inorganic nanoparticles applied as functional therapeutics. Adv. Funct. Mater. 2021;31(12):2008171.
   Web of Science ®Google Scholar
• Tang W, Fan W, Lau J, et al. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019;48(11):2967–3014. doi:10.1039/c8cs00805a
   PubMed Web of Science ®Google Scholar
• Marino A, Camponovo A, Degl’Innocenti A, et al. Multifunctional temozolomide-loaded lipid superparamagnetic nanovectors: dual targeting and disintegration of glioblastoma spheroids by synergic chemotherapy and hyperthermia treatment. Nanoscale. 2019;11(44):21227–21248.
   PubMed Web of Science ®Google Scholar
• Imanifard S, Zarrabi A, Zarepour A, et al. Nanoengineered thermoresponsive magnetic nanoparticles for drug controlled release. Macromol. Chem. Phys. 2017;218(23):1700350.
   Web of Science ®Google Scholar
• Wang J, Fang J, Fang P, et al. Preparation of hollow core/shell Fe3O4 @graphene oxide composites as magnetic targeting drug nanocarriers. J Biomater Sci Polym Ed. 2017;28(4):337–349.
   PubMed Web of Science ®Google Scholar
• Wang LH, Sui L, Zhao PH, et al. A composite of graphene oxide and iron oxide nanoparticles for targeted drug delivery of temozolomide. Pharmazie. 2020;75(7):313–317.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Je JY, Cha S, et al. Synergistic combination of chemo-phototherapy based on temozolomide/ICG-loaded iron oxide nanoparticles for brain cancer treatment. Oncol Rep. 2019;42(5):1709–1724.
   PubMed Web of Science ®Google Scholar
• Afzalipour R, Khoei S, Khoee S, et al. Thermosensitive magnetic nanoparticles exposed to alternating magnetic field and heat-mediated chemotherapy for an effective dual therapy in rat glioma model. Nanomed Nanotechnol Biol Med. 2021;31:102319.
   PubMed Web of Science ®Google Scholar
• Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle (Georgetown, TX). 2011;10(3):507–517.
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W, et al. The role of MicroRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005;102(52):19075–19080.
   PubMed Web of Science ®Google Scholar
• Zhang C, Kang C, You Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol. 2009;34(6):1653–1660.
   PubMed Web of Science ®Google Scholar
• Bertucci A, Prasetyanto EA, Septiadi D, et al. Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small. 2015;11(42):5687–5695.
   PubMed Web of Science ®Google Scholar
• Afzalipour R, Khoei S, Khoee S, et al. Dual-targeting temozolomide loaded in folate-conjugated magnetic triblock copolymer nanoparticles to improve the therapeutic efficiency of rat brain gliomas. ACS Biomater. Sci. Eng. 2019;5(11):6000–6011.
   PubMed Web of Science ®Google Scholar
• Wang B, Guo H, Xu H, et al. The role of graphene oxide nanocarriers in treating gliomas. Front Oncol. 2022;12:736177.
   PubMed Web of Science ®Google Scholar
• Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine (Lond). 2015;10(13):1993–1995.
   PubMed Web of Science ®Google Scholar
• Brenner JS, Bhamidipati K, Glassman PM, et al. Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine. 2017;13(4):1495–1506.
   PubMedGoogle Scholar
• Nelemans LC, Gurevich L. Drug delivery with polymeric nanocarriers—cellular uptake mechanisms. Materials. 2020;13(2):366.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6(8):583–592.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63(3):131–135.
   PubMed Web of Science ®Google Scholar
• Vyas D, Patel M, Wairkar S. Strategies for active tumor targeting-an update. Eur J Pharmacol. 2022;915:174512.
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99(19):1441–1454.
   PubMed Web of Science ®Google Scholar
• Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63(8):623–639.
   PubMed Web of Science ®Google Scholar
• Noh H, Zhao Q, Yan J, et al. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett. 2018;433:176–185.
   PubMed Web of Science ®Google Scholar
• Ramalho MJ, Sevin E, Gosselet F, et al. Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm. 2018;545(1-2):84–92.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee SJ, Lee DY. Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor. Bioact Mater. 2022;8:35–48.
   PubMed Web of Science ®Google Scholar
• Fu S, Xu X, Ma Y, et al. RGD peptide-based non-viral gene delivery vectors targeting integrin αv β3 for cancer therapy. J Drug Target. 2019;27(1):1–11.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao X, Zhu J, et al. Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomedicine. 2018;13:3039–3051. volume
   PubMed Web of Science ®Google Scholar
• Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–170.
   PubMed Web of Science ®Google Scholar
• Rehman S, Nabi B, Zafar A, et al. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson’s disease treatment? Expert Opin Drug Deliv. 2019;16(12):1355–1366.
   PubMed Web of Science ®Google Scholar
• Orza A, Soriţău O, Tomuleasa C, et al. Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles. Int J Nanomedicine. 2013;8:689–702.
   PubMed Web of Science ®Google Scholar
• Behroozi Z, Rahimi B, Kookli K, et al. Distribution of gold nanoparticles into the brain: a systematic review and meta-analysis. Nanotoxicology. 2021;15(8):1059–1072.
   PubMed Web of Science ®Google Scholar
• Aranda E, López-Pedrera C, De La Haba-Rodriguez JR, et al. Nitric oxide and cancer: the emerging role of S-nitrosylation. Curr Mol Med. 2012;12(1):50–67.
   PubMed Web of Science ®Google Scholar
• Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005;65(2):516–525.
   PubMed Web of Science ®Google Scholar
• Tsai C, Huang L, Wu Y, et al. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. Faseb J. 2019;33(12):14171–14184.
   PubMed Web of Science ®Google Scholar
• Meng X, Zhao Y, Han B, et al. Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways. Nat Commun. 2020;11(1):594.
   PubMed Web of Science ®Google Scholar
• Gong W, Wang Z, Wan Y, et al. Downregulation of ABCG2 protein inhibits migration and invasion in U251 glioma stem cells. Neuroreport. 2014;25(8):625–632.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang Z, Sun G, et al. miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2. Neuromolecular Med. 2014;16(2):517–528.
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Dong Y, et al. Identification of 2-fluoropalmitic acid as a potential therapeutic agent against glioblastoma. Curr Pharm Des. 2020;26(36):4675–4684.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee H, Park CG, et al. STAT3 inhibitor ODZ10117 suppresses glioblastoma malignancy and prolongs survival in a glioblastoma xenograft model. Cells. 2020;9(3):722.
   PubMed Web of Science ®Google Scholar
• Wu D, Wang C. miR-155 regulates the proliferation of glioma cells through PI3K/AKT signaling. Front Neurol. 2020;11:297.
   PubMed Web of Science ®Google Scholar
• Dong Q, Wang D, Li L, et al. Biochanin a sensitizes glioblastoma to temozolomide by inhibiting autophagy. Mol Neurobiol. 2022;59(2):1262–1272.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Park MN, Rahman MH, et al. p53 modulation of autophagy signaling in cancer therapies: perspectives mechanism and therapeutic targets. Front Cell Dev Biol. 2022;10:761080.
   PubMed Web of Science ®Google Scholar
• Laffleur F, Bauer B. Progress in nasal drug delivery systems. Int J Pharm. 2021;607:120994.
   PubMedGoogle Scholar